Ontology highlight
ABSTRACT: Background
The US Food and Drug Administration (FDA) interchangeability guidelines state that the primary endpoint in a switching study should assess the impact of switching between the proposed interchangeable product and the reference product on clinical pharmacokinetics (PK) and pharmacodynamics (if available), as these assessments are generally sensitive to changes in immunogenicity and/or exposure that may arise due to switching. In addition, interchangeability designation requires no clinically meaningful difference in safety and efficacy of switching between the biosimilar and reference, compared with when using the reference product alone.Objectives
The aim of this study was to investigate the PK, immunogenicity, efficacy, and safety in participants undergoing repe
SUBMITTER: Feldman SR
PROVIDER: S-EPMC10197027 | biostudies-literature | 2023 Jul
REPOSITORIES: biostudies-literature